Evidence map›Paper›PMID 33968206›Full record

ArticleOncology letters2021

Oncolytic virotherapy with human telomerase reverse transcriptase promoter regulation enhances cytotoxic effects against gastric cancer.

Tomoya Kato, Mikihito Nakamori, Shuichi Matsumura, Masaki Nakamura, Toshiyasu Ojima, Hiroshi Fukuhara, Yasushi Ino, Tomoki Todo, Hiroki Yamaue

RetractedOpen access · diamondAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. HSV: The scout and assault for digestive system tumors.Frontiers in molecular biosciences · 2023
    Review
  3. Review
  4. Review
  5. Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors.Frontiers in cellular and infection microbiology · 2022
    Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Tomoya KatoSecond Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama 641-8510, Japan.
Mikihito NakamoriSecond Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama 641-8510, Japan.
Shuichi MatsumuraSecond Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama 641-8510, Japan.
Masaki NakamuraSecond Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama 641-8510, Japan.
Toshiyasu OjimaSecond Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama 641-8510, Japan.
Hiroshi FukuharaDepartment of Urology, Kyorin University, School of Medicine, Mitaka, Tokyo 181-8611, Japan.
Yasushi InoDivision of Innovative Cancer Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Tomoki TodoDivision of Innovative Cancer Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Hiroki YamaueSecond Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama 641-8510, Japan.
Wakayama Medical University · JPThe University of Tokyo · JPKyorin University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, gastric cancer is the third most common cause of cancer-associated mortality worldwide. Oncolytic virotherapy using herpes simplex virus (HSV) has emerged as a novel therapeutic strategy against cancer. Telomerase is activated in >90of malignant tumors, including gastric cancer, and human telomerase reverse transcriptase (hTERT) is one of the major components of telomerase enzyme. Therefore, in oncolytic HSV, placing the essential genes under the regulation of the hTERT promoter may enhance its antitumor efficacy. The present study examined the antitumor effect of fourth-generation oncolytic HSVs, which contain the

Indexed as

gastric cancerherpes simplex virushuman telomerase reverse transcriptase promoteroncolytic virotherapyoncolytic virus

Identifiers

PMID33968206
PMCPMC8100961
OpenAlexW3207842822

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.